Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-05-29

Molecular mechanisms of bone homeostasis

Objectif

Bone is a dynamic tissue that is continually remodelling throughout life. In all ageing people this profit and loss process favours loss of bone mass. Consequently, many develop osteoporosis with considerably enhanced susceptibility to fractures with up to 30 per cent mortality and massive, lasting morbidity. In fact, osteoporosis represents the most prevalent and incapacitating disease of women after 50 years of age and the increased incidence of the disease also among men has made it a serious threat to healthy ageing of both genders in Europe. The current project is focused on improving the understanding of the molecular mechanisms involved in bone homeostasis. A main emphasis, as required by the Work Programme, will be on the anabolic aspects. New knowledge is sought using contemporary array technology and functional genomics building on the recently definition of the human genome. A major target will be identification of the mRNAs and proteins that exercise a central role in the building (anabolic) phases of bone metabolism, including but not limited to those regulated by parathyroid hormone (PTH). Selective stimulation of anabolic effectors will, it is argued, form the basis for new treatment modalities that will increase new and fully-functional bone formation. This approach contrasts with many contemporary regimes of treatment that primarily inhibit bone resorption, thus increasing the amount of more or less worn tissue. A special attempt will be made to identify genetic markers that can be used for early identification of people at risk for later development of osteoporosis. The project will be undertaken by a multidisciplinary team including medical practitioners, molecular and cellular biologists and biochemists all with an international track record. The long-term aim will be a reduction in the impact of osteoporosis in Europe brought about by application of appropriate evidence-based therapeutic and preventive medicine.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Appel à propositions

FP6-2002-LIFESCIHEALTH
Voir d’autres projets de cet appel

Régime de financement

STREP - Specific Targeted Research Project

Coordinateur

ULLEVAEL UNIVERSITY HOSPITAL
Contribution de l’UE
Aucune donnée
Adresse
Kirkeveien, 166
OSLO
Norvège
Coût total
Aucune donnée

Participants (7)